Valérie André

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy et al. · The Lancet Oncology · 2022 · 566 citations · Full text

Medicine, Endocrinology, Oncology +14

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín et al. · Annals of Oncology · 2021 · 378 citations · Full text

Medicine, Oncology, Pharmacology +16

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

M.P. Goetz, M. Toi, Jens Huober et al. · Annals of Oncology · 2024 · 206 citations · Full text

Medicine, Oncology, Pharmacology +16

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Priya Rastogi, Joyce O’Shaughnessy, Miguel Martín et al. · Journal of Clinical Oncology · 2024 · 204 citations · Full text

Medicine, Oncology, Pharmacology +15

Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

Hope S. Rugo, Jens Huober, José Á. García-Sáenz et al. · The Oncologist · 2020 · 172 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17